Randomized, placebo-controlled window trial of EGFR, Src, or combined blockade in head and neck cancerJulie E. Bauman, Jennifer R. Grandis, Neil D. Gross et al.|JCI Insight|2017Cited by 55
Erlotinib, dasatinib, erlotinib-dasatinib versus placebo: A randomized, double-blind window study in operable head and neck squamous cell carcinoma (HNSCC).Julie E. Bauman, Jennifer R. Grandis, Umamaheswar Duvvuri et al.|Journal of Clinical Oncology|2014Cited by 5